2020-12-18 åå€å±å€§åŠ,æ¥æ¬å»çç ç©¶éçºæ©æ§
åå€å±å€§åŠå»åŠéšéå±ç é¢å 端å»çéçºéš/å倧å»åŠç³»ç ç©¶ç§ç²Ÿç¥å»åŠã®æå²¡ç¥åç¹ä»»è¬åž«ãå倧å»åŠç³»ç ç©¶ç§ç²Ÿç¥å»åŠã®å°ŸåŽçŽå€«ææãã®ç ç©¶ã°ã«ãŒãã¯ãiPS现èâ»1ãçšããè§£æãããæå®é£ç ã®äžã€ã§ãã22q11.2æ¬ å€±çå矀(22q11.2DS)â»2ã®è³å ååç æ ãšããŠããäžè³ãããã³ç¥çµçްèâ»3ã«ãããPRKR-Like Endoplasmic Reticulum Kinase(PERK)â»4äŸåçãªè匱æ§ããèŠåºããŸããã
22q11.2DSæ£è ã¯ãåã©ã€ãã¹ããŒãžã«å¿ããŠãç¥çèœåé害ãèªéã¹ãã¯ãã©ã çãæ³šææ¬ åŠã»å€åçãçµ±å倱調çãè¥å¹ŽåããŒãã³ãœã³ç ãªã©å€æ§ãªç²Ÿç¥ã»ç¥çµçŸæ£ãçºçããŸããããããªãããæ£è ã®è³ã®äžã§äœãèµ·ããŠããã®ãããçŽæ¥ååã»çްèã¬ãã«ã§èª¿ã¹ãæ¹æ³ããªãããšããã22q11.2DSã®è³å ç æ ã¯äžæãªç¹ãå€ãæ®ãããŠããŸãã
ãããŸã§ã®22q11.2DSã®è³å ç æ è§£æãç®æããç ç©¶ã®å€ãã¯ã粟ç¥çŸæ£ãšã®é¢é£ã ãã«çç®ããŠãããã®ã§ãããä»åã粟ç¥çŸæ£ã ãã§ã¯ãªããç¥çµçŸæ£ã§ããããŒãã³ãœã³ç ãšã®é¢é£ã«ãçç®ããŠæ€èšãããããäž¡çŸæ£ã«æ·±ãé¢é£ããäžè³ãããã³ç¥çµçްèãè§£æå¯Ÿè±¡ãšããŸããã22q11.2DSæ£è ãšå¥åžžè ã«ååãåŸãŠãæš¹ç«ããiPS现èãããããã³ç¥çµçްèãäœè£œããå¥åžžè ãšæ£è ã®éãã調ã¹ãŸãããå¥åžžè ãšæ£è ã®ã¿ã³ãã¯è³ªçºçŸãç¶²çŸ çã«æ¯èŒãããšãããæ£è ã§ã¯ãå°èäœâ»5ã®æ©èœã«é¢ããã¿ã³ãã¯è³ªçŸ€ã®çºçŸãäœäžããŠãããç¹ã«PERKãšããã¿ã³ãã¯è³ªã®é¡èãªæ©èœäžå šãçããŠããŸããããã®PERKã®æ©èœäžå šãå埩ãããããšã§ãæ£è ã§èªããããæ§ã ãªçްèè匱æ§ã®äžéšãæ¹åã§ããããšãããããŸããã
22q11.2DSæ£è ã¯ãçæ¶¯ã«ããã倿§ãªç²Ÿç¥ã»ç¥çµçŸæ£ã®çºçãªã¹ã¯ãæ±ãç¶ããŸããåœäºè ã»ãå®¶æããã22q11.2æ¬ å€±ãåå®ãããçºçã®å¯èœæ§ãåãã£ãŠããã®ã§ããã°ãé²å±ãæ¢ããæ¹æ³ã®éçºãããšã®æ³ãã䌺ã£ãŠããŸããæ¬ç ç©¶ææã¯ã22q11.2DSæ£è ã®ç²Ÿç¥ã»ç¥çµçŸæ£ã«å¯Ÿããæ²»çè¬éçºãå°æ¥çãªçºçäºé²ãå³ã¡åœäºè ã»ãå®¶æã®æ³ãã«å¿ããããšãããã«å€æ§ãªç²Ÿç¥ã»ç¥çµçŸæ£ã®ç æ è§£æãšæ ¹æ¬çæ²»çæ³éçºãžè²¢ç®ããããšãæåŸ ãããŸãã
ãã®ç ç©¶ææã¯ãThe LancetãšCell pressãå ±åçºè¡ããŠããéèªãEBioMedicineã(2020幎12æ17æ¥ä»ã)ã®é»åçã«æ²èŒãããŸããæ¬ç ç©¶çµæã¯ã驿°çæè¡ã«ããè³æ©èœãããã¯ãŒã¯ã®å šå®¹è§£æãããžã§ã¯ã(驿°è³)ãè³ç§åŠç ç©¶æŠç¥æšé²ããã°ã©ã (çºéé害ã»çµ±å倱調ççã®å æã«é¢ããç ç©¶)ã®æ¯æŽãåããŠè¡ãããŸããã
ãã€ã³ã
- 22q11.2æ¬ å€±çå矀(22q11.2DS)æ£è ã¯ãåã©ã€ãã¹ããŒãžã«å¿ããŠå€æ§ãªç²Ÿç¥ã»ç¥çµçŸæ£ãçºçããŸããããããæ£è ã®è³ã®äžã§äœãèµ·ããŠããã®ãããçŽæ¥ååã»çްèã¬ãã«ã§èª¿ã¹ãæ¹æ³ããªãããšããã22q11.2DSã«ãã£ãŠè³å ã«äœãèµ·ãããçºçã«ç¹«ããã®ãã¯æªã äžæãªç¹ãå€ãæ®ãããŠããŸãã
- 22q11.2DSæ£è ãšå¥åžžè ã«ååãåŸãŠãæš¹ç«ããiPS现èãçšããŠäžè³ã«å€ããããã³ç¥çµçްèãäœè£œããå¥åžžè ãšæ£è ã®éãã調ã¹ãŸããã
- 22q11.2DSæ£è ã®ãããã³ç¥çµçްèã§ã¯ãPRKR-Like Endoplasmic Reticulum Kinase(PERK)ã®æ©èœäžå šã«ãã£ãŠæ§ã ãªè匱æ§ãçããŠããããšãæããã«ãªããŸããã
- æ¬ç ç©¶ææã¯ã22q11.2DSæ£è ã®ç²Ÿç¥ã»ç¥çµçŸæ£ã®ç æ è§£æã ãã§ã¯ãªããå°æ¥çãªçºçäºé²ãæ ¹æ¬çæ²»çæ³éçºã«ç¹«ããããšãæåŸ ãããŸãã
èæ¯
22q11.2æ¬ å€±çå矀(22q11.2DS)ã¯ãè³ãã¯ããå¿åŸªç°ç³»ãå ç«ç³»ãå åæ³ç³»ãªã©è€æ°ã®èåšã«åœ±é¿ãåãŒããŸãããã®çµæã22q11.DSæ£è ã¯åã©ã€ãã¹ããŒãžã«å¿ããŠãå€èåšçŸæ£ãšãšãã«ç¥çèœåé害ãèªéã¹ãã¯ãã©ã çãæ³šææ¬ åŠã»å€åçãçµ±å倱調çãè¥å¹ŽåããŒãã³ãœã³ç ãªã©å€æ§ãªç²Ÿç¥ã»ç¥çµçŸæ£ãçºçããŸããããããæ£è ã®è³ã®äžã§äœãèµ·ããŠããã®ãããçŽæ¥ååã»çްèã¬ãã«ã§èª¿ã¹ãæ¹æ³ããªãããšããã22q11.2DSã®è³å ç æ ã¯æªã äžæãªç¹ãå€ãæ®ãããŠããŸãããã®ããã22q11.2DSæ£è ã¯ç²Ÿç¥ã»ç¥çµçŸæ£ãçºçããå¯èœæ§ãåãã£ãŠããã«ãããããããä»åŸèµ·ããåŸãçŸæ£çºçã®äºé²ããçŸæ£ã®é²è¡ãæ¢ããæ¹æ³ããªãã®ãçŸç¶ã§ãã
ç ç©¶ææ
ãããŸã§ã®22q11.2DSã®è³ç æ è§£æã«åããç ç©¶ã§ã¯ã粟ç¥çŸæ£ãšã®é¢é£ã®ã¿ã«çŠç¹ã¥ããããŠããããšãå€ãããã®ããè³é åãšããŠå€§è³ç®è³ªâ»6ãæµ·éЬâ»7ã察象ãšããç ç©¶ã倧åã§ãããä»åã粟ç¥çŸæ£ã ãã§ã¯ãªããããŒãã³ãœã³ç ãšã®é¢é£ãæ€èšãããããäž¡çŸæ£ã«æ·±ãé¢é£ããäžè³ãããã³ç¥çµçްèãè§£æå¯Ÿè±¡ãšããå¥åžžè ãš22q11.2DSæ£è ããæš¹ç«ããiPS现èãçšããŠãããã³ç¥çµçްèãäœè£œããå¥åžžè ãšæ£è ã®éãã調ã¹ãŸããã
æ£è ãšå¥åžžè ã®iPS现èç±æ¥ã®ãããã³ç¥çµçްèã«ã€ããŠãã¿ã³ãã¯è³ªçºçŸãç¶²çŸ çã«æ¯èŒãããšãããæ£è ã§ã¯ãå°èäœã®æ©èœã«é¢ããã¿ã³ãã¯è³ªçŸ€ã®çºçŸãäœäžããŠããŸãããå°èäœã«ã¯æ§ã ãªçççã¹ãã¬ã¹(=å°èäœã¹ãã¬ã¹â»8)ãåããå Žåã§ããæåžžæ§ãç¶æããããã®ã·ã¹ãã ãåãã£ãŠããŸãããæ£è ã§ã¯ãããã®ã·ã¹ãã ã«ç°åžžãããããšãäºæ³ãããŸãããããã§ãå°èäœã¹ãã¬ã¹å¿çã«é¢ããã¿ã³ãã¯è³ªããã®é¢é£ã·ã°ãã«ã詳现ã«è§£æãããšãããç¹ã«PERKãšããã¿ã³ãã¯è³ªã®çºçŸäœäžãšãšãã«ãã®äžæµã·ã°ãã«ã®æŽ»æ§åãäœäžããŠãããPERKã®é¡èãªæ©èœäžå šãçããŠããããšãããããŸãããããã«äžèŽããããã«ãæ£è ã®ãããã³ç¥çµçްèã§ã¯ãå°èäœã¹ãã¬ã¹ãžã®èæ§ãäœäžããŠããŸãããããã«ãF-ã¢ã¯ãã³â»9åæ ã®ç°åžžãå°èäœâããã³ã³ããªã¢ã®æ¥è§Šâ»10äœäžãã¿ã³ãã¯è³ªåæäœäžãšãã£ãã粟ç¥ã»ç¥çµçŸæ£ã®ç æ ãåæ ãããããªè¡šçŸåç°åžžãèªããããŸããããããã®äžéšã¯ãPERKã®æ©èœäžå šãå埩ããã(PERK掻æ§å€ã§ããSalubrinalã®æ·»å )ããšã§æ¹åã§ããããšãããããŸãã(å³1)ã

å³1ãæ£è ã«ãããF-ã¢ã¯ãã³åæ ç°åžžãšPERK掻æ§åã«ããæ¹å
- æ£è ã§ã¯å¥åžžè ã«æ¯ã¹ãŠF-ã¢ã¯ãã³åæ ç°åžž(èç¶æ§é ãæ¶å€±ããŠéç¶æ§é ãé·ã)ã瀺ããã
- PERKã®æŽ»æ§åã«ãã£ãŠæ¹åãèªããããã
次ã«ãã©ãããŠ22q11.2DSã§ã¯PERKã®çºçŸãäœäžãããã調ã¹ãŸããã22q11.2DSã§ã¯ã40以äžã®éºäŒåããããæ¬ 倱â»11ã«ãªã£ãŠããŸãããããéºäŒåã®ãã¡ãDGCR14ãšåŒã°ããéºäŒåãäœäžãããšãPERKã®çºçŸãäœããªãããšãããããŸãããDGCR14éºäŒåã®ãããæ¬ 倱ããPERKã®æ©èœäžå šã«é¢äžããŠããå¯èœæ§ã瀺åãããŸãã(å³2)ã

å³2ãDGCR14éºäŒåãšPERKã¿ã³ãã¯è³ª
DGCR14éºäŒåã®çºçŸãäœäžããã现èã§ã¯PERKã¿ã³ãã¯è³ªã®çºçŸãäœäžããŠããã
ä»åŸã®å±é
æ¬ç ç©¶ææã¯ã22q11.2DSæ£è ã§çãã粟ç¥ã»ç¥çµçŸæ£ã®è³å ååç æ ãšããŠããããã³ç¥çµçްèã«ãããPERKäŸåçãªè匱æ§ãã®ååšã瀺ãããã®ã§ã(å³3)ã22q11.2DSæ£è ã®ç²Ÿç¥ã»ç¥çµçŸæ£ã«å¯Ÿããç æ ã«åºã¥ãæ²»çè¬ã®éçºããå°æ¥ã«çãåŸã粟ç¥ã»ç¥çµçŸæ£ã®çºçäºé²æ³ã®éçºã«ã€ãªããäžæ©ãšèããŠãããŸããããã«ã¯å€æ§ãªç²Ÿç¥ã»ç¥çµçŸæ£ã®ç æ è§£æãšæ ¹æ¬çæ²»çæ³éçºãžè²¢ç®ããããšãæåŸ ãããŸãã

å³3ããããã³ç¥çµçްèã«ãããPERKäŸåçãªè匱æ§
çšèªèª¬æ
- â»1ãiPS现è
- æ§ã ãªçµç¹ãèåšã®çްèã«ååããèœåãšã»ãŒç¡éã«å¢æ®ããèœåããã€çްèãè¡æ¶²ãªã©ã®äœçްèããã€ããããšãã§ããã
- â»2ã22q11.2æ¬ å€±çå矀
- æè²äœåŸ®çŽ°æ¬ å€±çå矀ã«å«ãŸããæå®é£ç ã§ã4000人ã®1人ã®å²åã§åå®ããããå€èåšã«åã¶å¹ åºãèšåºåã瀺ãã忰以äžãå 倩æ§å¿çŸæ£ãå䜵ããå¹Œå°æã«æè¡çæ²»çãå¿ èŠãšããå Žåãå€ãã忣è ã¯å¿èæè¡ã«ããçåãåŸãŠããçŽ90%ãç¥çèœåéå®³ãæŽã«èªéã¹ãã¯ãã©ã çãçµ±å倱調çãªã©ã®ç²Ÿç¥çŸæ£ã«å ããŠãè¥å¹ŽåããŒãã³ãœã³ç ãªã©ã®ç¥çµå€æ§çŸæ£ããšãã£ã倿§ãªç²Ÿç¥ã»ç¥çµçŸæ£çºçã®é«ããªã¹ã¯ãæããã
- â»3ãäžè³ãããã³ç¥çµçްè
- è³ãæ§æããç¥çµçްèã®äžçš®ãäžè³ã§ã€ãããããæçãããšç¥çµäŒéç©è³ªã§ãããããã³ãåæ³ãããäžè³ã®ãããã³ç¥çµçްèã倱ããããããã³ç£çéãæžå°ãããšããŒãã³ãœã³ç ãçºçãããäžè³ãããã³ç¥çµç³»ã®æ©èœ(ææ¬²ãææ )é害ã¯å€ãã®ç²Ÿç¥çŸæ£ã«ãæ·±ãé¢ãã£ãŠããã
- â»4ãPRKR-Like Endoplasmic Reticulum Kinase(PERK)
- å°èäœã®ã¹ãã¬ã¹ã»ã³ãµãŒã¿ã³ãã¯è³ªã®ã²ãšã€ãå°èäœãçççã¹ãã¬ã¹ãåãããšãæåžžæ§ãç¶æããããšããŠãPERKã®ã·ã°ãã«ã掻æ§åãããè¿å¹Žã§ã¯ãPERKã¯èªç¥ãèšæ¶ãå路圢æãªã©ã®ç¥çµæ©èœã«ãé¢äžããŠããããšãå ±åãããŠããã
- â»5ãå°èäœ
- 现èå°åšå®ã®ã²ãšã€ãã¿ã³ãã¯è³ªã®æ§ã ãªããã»ã·ã³ã°ã«é¢äžããŠããã
- â»6ã倧è³ç®è³ª
- è³é åã®ã²ãšã€ãèªç¥ã»å€æã»èšèªãªã©ãšãã£ãããã®é«åºŠãªç²Ÿç¥æ©èœãæ ãé åãšèããããŠããã
- â»7ãæµ·éЬ
- è³é åã®ã²ãšã€ãèšæ¶ãåŠç¿èœåãæ ãé åãšèããããŠããã
- â»8ãå°èäœã¹ãã¬ã¹
- 倿§ããã¿ã³ãã¯è³ªãå°èäœã«èç©ãããªã©ã®å°èäœãžã®åºæ¿ã®ããšãæ£åžžãªçްèã§ã¯å°èäœã¹ãã¬ã¹ãåé¿ããã·ã¹ãã ãåãã£ãŠããããã®ã·ã¹ãã ã®ã²ãšã€ãPERKã¯æ ã£ãŠããã
- â»9ãF-ã¢ã¯ãã³
- 现èéªšæ Œã®ã²ãšã€ãã·ããã¹åœ¢æãç¥çµåè·¯æ§ç¯ã«é¢äžããã
- â»10ãå°èäœâããã³ã³ããªã¢ã®æ¥è§Š
- å°èäœãšããã³ã³ããªã¢ã¯ãæ¥è§Šããããšã§ã«ã«ã·ãŠã ãªã©æ§ã ãªç©è³ªã®åãæž¡ããã³ãã¥ãã±ãŒã·ã§ã³ãè¡ã£ãŠããããã®æ¥è§Šã«é¢ããç°åžžã粟ç¥ã»ç¥çµçŸæ£ã®çºçã«é¢äžãããšããããŠããã
- â»11ããããæ¬ 倱
- æã ã¯äž¡èŠªãã1ã»ãããã€ã®éºäŒæ å ±ãåãç¶ãã§ããããã®ãã¡ã®çæ¹ãæ¬ ããŠããç¶æ ããããæ¬ 倱ãšããã
çºè¡šéèª
- æ²èŒèªå
- EBioMedicine
- è«æã¿ã€ãã«
- Chromosome 22q11.2 deletion causes PERK-dependent vulnerability in dopaminergic neurons
- èè
- Yuko Arioka1, 2, 3, Emiko Shishido1, 4, Itaru Kushima1, 5, Toshiaki Suzuki1, Ryo Saito6, Atsu Aiba6, Daisuke Mori1, 7, Norio Ozaki1
- æå±
-
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
- Institute for Advanced Research, Nagoya University, Nagoya, Japan
- National Institute for Physiological Sciences, Okazaki, Japan
- Medical Genomics Center, Nagoya University Hospital, Nagoya, Japan
- Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Brain and Mind Research Center, Nagoya University, Nagoya, Japan
- DOI
- 10.1016/j.ebiom.2020.103138
åœãªãªãŒã¹ã«é¢ããŠãããŸã§ã«å ±åããåœéç§åŠè«æ
ã22q11.2æ¬ å€±ã
- ã²ãã è§£æ:
- Kushima I, Aleksic B, Nakatochi M, Shimamura T, Okada T, Uno Y, Morikawa M, Ishizuka K, Shiino T, Kimura H, Arioka Y, Yoshimi A, Takasaki Y, Yu Y, Nakamura Y, Yamamoto M, Iidaka T, Iritani S, Inada T, Ogawa N, Shishido E, Torii Y, Kawano N, Omura Y, Yoshikawa T, Uchiyama T, Yamamoto T, Ikeda M, Hashimoto R, Yamamori H, Yasuda Y, Someya T, Watanabe Y, Egawa J, Nunokawa A, Itokawa M, Arai M, Miyashita M, Kobori A, Suzuki M, Takahashi T, Usami M, Kodaira M, Watanabe K, Sasaki T, Kuwabara H, Tochigi M, Nishimura F, Yamasue H, Eriguchi Y, Benner S, Kojima M, Yassin W, Munesue T, Yokoyama S, Kimura R, Funabiki Y, Kosaka H, Ishitobi M, Ohmori T, Numata S, Yoshikawa T, Toyota T, Yamakawa K, Suzuki T, Inoue Y, Nakaoka K, Goto YI, Inagaki M, Hashimoto N, Kusumi I, Son S, Murai T, Ikegame T, Okada N, Kasai K, Kunimoto S, Mori D, Iwata N, *Ozaki N, Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights, Cell Rep 24 (11):2838-2856 (2018)
- ã¢ãã«ããŠã¹:
- Saito R, Koebis M, Nagai T, Shimizu K, Liao J, Wulaer B, Sugaya Y, Nagahama K, Uesaka N, Kushima I, Mori D, Maruyama K, Nakao K, Kurihara H, Yamada K, Kano M, Fukada Y, Ozaki N, Aiba A, Comprehensive analysis of a novel mouse model of the 22q11.2 deletion syndrome: a model with the most common 3.0-Mb deletion at the human 22q11.2 locus, Transl Psychiatry 10 (1):35 (2020)
- æ»åŸè³:
- Torii Y, Iritani S, Marui T, Sekiguchi H, Habuchi C, Fujishiro H, Kushima I, Oshima K, Niizato K, Hayashida S, Masaki K, Kira JI, Yoshida M, Ozaki N, Morphological alteration of myelin-oligodendrocytes in a schizophrenic patient with 22q11.2 deletion syndrome: An autopsy study, Schizophr Res (in press)
ã粟ç¥çŸæ£çºçãªã¹ã¯ã²ãã å€ç°ãæããæ£è iPS现èã®è§£æã
- RELN:
- Arioka Y, Shishido E, Kubo H, Kushima I, Yoshimi A, Kimura H, Ishizuka K, Aleksic B, Maeda T, Ishikawa M, Kuzumaki N, Okano H, Mori D, Ozaki N, Single-cell trajectory analysis of human homogenous neurons carrying a rare RELN variant, Transl Psychiatry 8 (1):129 (2018)
Arioka Y, Shishido E, Kushima I, Mori D, Ozaki N, Cell body shape and directional movement stability in human-induced pluripotent stem cell-derived dopaminergic neurons, Sci Rep 10 (1):5820 (2020) - ARHGAP10:
- Sekiguchi M, Sobue A, Kushima I, Wang C, Arioka Y, Kato H, Kodama A, Kubo H, Ito N, Sawahata M, Hada K, Ikeda R, Shinno M, Mizukoshi C, Tsujimura K, Yoshimi A, Ishizuka K, Takasaki Y, Kimura H, Xing J, Yu Y, Yamamoto M, Okada T, Shishido E, Inada T, Nakatochi M, Takano T, Kuroda K, Amano M, Aleksic B, Yamomoto T, Sakuma T, Aida T, Tanaka K, Hashimoto R, Arai M, Ikeda M, Iwata N, Shimamura T, Nagai T, Nabeshima T, Kaibuchi K, *Yamada K, *Mori D, Ozaki N, ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk, Transl Psychiatry 10 (1):247 (2020)
- PCDH15:
- Ishii T, Ishikawa M, Fujimori K, Maeda T, Kushima I, Arioka Y, Mori D, Nakatake Y, Yamagata B, Nio S, Kato TA, Yang N, Wernig M, Kanba S, Mimura M, Ozaki N, Okano H, In Vitro Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of PCDH15 and RELN, eNeuro 6 (5):(2019)
ãåãåããå
ç ç©¶ã«ã€ããŠ
åå€å±å€§åŠå»åŠéšã»å»åŠç³»ç ç©¶ç§
粟ç¥å»åŠãææãå°ŸåŽçŽå€«
åºå ±æ åœ
åå€å±å€§åŠå»åŠéšã»å»åŠç³»ç ç©¶ç§ç·å課ç·åä¿
AMEDäºæ¥ã«ã€ããŠ
åœç«ç ç©¶éçºæ³äººæ¥æ¬å»çç ç©¶éçºæ©æ§
çŸæ£åºç€ç ç©¶äºæ¥éšçŸæ£åºç€ç 究課
驿°çæè¡ã«ããè³æ©èœãããã¯ãŒã¯ã®å
šå®¹è§£æãããžã§ã¯ã
è³ç§åŠç ç©¶æŠç¥æšé²ããã°ã©ã

